Jun He

cDr. Caforio has been CEO of Bristol Myers Squibb since May 2015 and assumed the role of Chairman of the Board in May 2017. As CEO, Dr. Caforio oversaw the acquisition of Celgene and has led the company’s focus on researching and developing transformational medicines, which includes leading portfolios in oncology, hematology, immunology and cardiovascular disease. Previously, he spent 12 years with Abbott Laboratories in a number of leadership positions. Dr. Caforio also served as the Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), a trade association representing pharmaceutical companies in the United States. Dr. Caforio adds extensive experience to our board as both a physician and a business leader. As CEO of a leading global biopharmaceutical company, he has advanced scientific innovation that has helped improve the lives of patients. This experience will enable him to provide valuable business, leadership and management insights to our board.